Advances in PET imaging of cancer.

Humans Positron Emission Tomography Computed Tomography / methods Positron-Emission Tomography Neoplasms / diagnostic imaging Magnetic Resonance Imaging Machine Learning

Journal

Nature reviews. Cancer
ISSN: 1474-1768
Titre abrégé: Nat Rev Cancer
Pays: England
ID NLM: 101124168

Informations de publication

Date de publication:
07 2023
Historique:
accepted: 17 04 2023
medline: 28 6 2023
pubmed: 1 6 2023
entrez: 31 5 2023
Statut: ppublish

Résumé

Molecular imaging has experienced enormous advancements in the areas of imaging technology, imaging probe and contrast development, and data quality, as well as machine learning-based data analysis. Positron emission tomography (PET) and its combination with computed tomography (CT) or magnetic resonance imaging (MRI) as a multimodality PET-CT or PET-MRI system offer a wealth of molecular, functional and morphological data with a single patient scan. Despite the recent technical advances and the availability of dozens of disease-specific contrast and imaging probes, only a few parameters, such as tumour size or the mean tracer uptake, are used for the evaluation of images in clinical practice. Multiparametric in vivo imaging data not only are highly quantitative but also can provide invaluable information about pathophysiology, receptor expression, metabolism, or morphological and functional features of tumours, such as pH, oxygenation or tissue density, as well as pharmacodynamic properties of drugs, to measure drug response with a contrast agent. It can further quantitatively map and spatially resolve the intertumoural and intratumoural heterogeneity, providing insights into tumour vulnerabilities for target-specific therapeutic interventions. Failure to exploit and integrate the full potential of such powerful imaging data may lead to a lost opportunity in which patients do not receive the best possible care. With the desire to implement personalized medicine in the cancer clinic, the full comprehensive diagnostic power of multiplexed imaging should be utilized.

Identifiants

DOI: 10.1038/s41568-023-00576-4 PMID: 37258875
pubmed: 37258875
doi: 10.1038/s41568-023-00576-4
pii: 10.1038/s41568-023-00576-4
doi:

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

474-490

Informations de copyright

© 2023. Springer Nature Limited.

Références

Marusyk, A. & Polyak, K. Tumor heterogeneity: causes and consequences. Biochim. Biophys. Acta 1805, 105–117 (2010).
Dagogo-Jack, I. & Shaw, A. T. Tumour heterogeneity and resistance to cancer therapies. Nat. Rev. Clin. Oncol. 15, 81–94 (2018).
pubmed: 29115304 doi: 10.1038/nrclinonc.2017.166
Marusyk, A., Janiszewska, M. & Polyak, K. Intratumor heterogeneity: the Rosetta stone of therapy resistance. Cancer Cell 37, 471–484 (2020).
pmcid: 7181408 doi: 10.1016/j.ccell.2020.03.007
Saunders, N. A. et al. Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives. EMBO Mol. Med. 4, 675–684 (2012).
pmcid: 3494067 doi: 10.1002/emmm.201101131
Hyman, D. M., Taylor, B. S. & Baselga, J. Implementing genome-driven oncology. Cell 168, 584–599 (2017).
pmcid: 5463457 doi: 10.1016/j.cell.2016.12.015
Keller, L. & Pantel, K. Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells. Nat. Rev. Cancer 19, 553–567 (2019). This review discusses how tumour heterogeneity can be analysed by profiling tumour cells in circulation.
doi: 10.1038/s41568-019-0180-2
Joosse, S. A. & Pantel, K. Circulating DNA and liquid biopsies in the management of patients with cancer. Cancer Res. 82, 2213–2215 (2022).
doi: 10.1158/0008-5472.CAN-22-1405
Mannheim, J. G. et al. PET/MRI hybrid systems. Semin. Nucl. Med. 48, 332–347 (2018). This review summarizes the different PET–MRI systems for multimodal preclinical and clinical imaging.
doi: 10.1053/j.semnuclmed.2018.02.011
Seifert, R. et al. Clinical use of PET/MR in oncology: an update. Semin. Nucl. Med. 52, 356–364 (2022).
doi: 10.1053/j.semnuclmed.2021.11.012
Wehrl, H. F., Sauter, A. W., Divine, M. R. & Pichler, B. J. Combined PET/MR: a technology becomes mature. J. Nucl. Med. 56, 165–168 (2015).
pubmed: 25593114 doi: 10.2967/jnumed.114.150318
Herrmann, K. et al. Radiotheranostics: a roadmap for future development. Lancet Oncol. 21, e146–e156 (2020).
pubmed: 32135118 pmcid: 7367151 doi: 10.1016/S1470-2045(19)30821-6
Weissleder, R., Schwaiger, M. C., Gambhir, S. S. & Hricak, H. Imaging approaches to optimize molecular therapies. Sci. Transl. Med. 8, 355ps316 (2016).
doi: 10.1126/scitranslmed.aaf3936
Divine, M. R. et al. A population-based Gaussian mixture model incorporating
pubmed: 26659350 doi: 10.2967/jnumed.115.163972
Katiyar, P. et al. Spectral clustering predicts tumor tissue heterogeneity using dynamic
pubmed: 27811120 doi: 10.2967/jnumed.116.181370
Katiyar, P. et al. A novel unsupervised segmentation approach quantifies tumor tissue populations using multiparametric MRI: first results with histological validation. Mol. Imaging Biol. 19, 391–397 (2017).
pubmed: 27734253 doi: 10.1007/s11307-016-1009-y
Zaharchuk, G. & Davidzon, G. Artificial intelligence for optimization and interpretation of PET/CT and PET/MR images. Semin. Nucl. Med. 51, 134–142 (2021). This review describes the use of MI and AI for multimodal imaging.
pubmed: 33509370 doi: 10.1053/j.semnuclmed.2020.10.001
Beyer, T. et al. A combined PET/CT scanner for clinical oncology. J. Nucl. Med. 41, 1369–1379 (2000).
pubmed: 10945530
Judenhofer, M. S. et al. Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat. Med. 14, 459–465 (2008).
pubmed: 18376410 doi: 10.1038/nm1700
Shao, Y. et al. Simultaneous PET and MR imaging. Phys. Med. Biol. 42, 1965–1970 (1997).
pubmed: 9364592 doi: 10.1088/0031-9155/42/10/010
Wehrl, H. F. et al. Preclinical and translational PET/MR imaging. J. Nucl. Med. 55, 11S–18S (2014).
pubmed: 24833493 doi: 10.2967/jnumed.113.129221
Provost, J. et al. Simultaneous positron emission tomography and ultrafast ultrasound for hybrid molecular, anatomical and functional imaging. Nat. Biomed. Eng. 2, 85–94 (2018).
pubmed: 31015628 doi: 10.1038/s41551-018-0188-z
Wehrl, H. F. et al. Assessment of MR compatibility of a PET insert developed for simultaneous multiparametric PET/MR imaging on an animal system operating at 7 T. Magn. Reson. Med. 65, 269–279 (2011).
pubmed: 20806353 pmcid: 3004988 doi: 10.1002/mrm.22591
Judenhofer, M. S. & Cherry, S. R. Applications for preclinical PET/MRI. Semin. Nucl. Med. 43, 19–29 (2013).
pubmed: 23178086 doi: 10.1053/j.semnuclmed.2012.08.004
Sauter, A. W., Wehrl, H. F., Kolb, A., Judenhofer, M. S. & Pichler, B. J. Combined PET/MRI: one step further in multimodality imaging. Trends Mol. Med. 16, 508–515 (2010).
pubmed: 20851684 doi: 10.1016/j.molmed.2010.08.003
Asa, S. et al. Hybrid Ga-68 prostate-specific membrane antigen PET/MRI in the detection of skeletal metastasis in patients with newly diagnosed prostate cancer: contribution of each part to the diagnostic performance. Nucl. Med. Commun. 44, 65–73 (2023).
pubmed: 36378618 doi: 10.1097/MNM.0000000000001637
Wehrl, H. F. et al. Multimodal elucidation of choline metabolism in a murine glioma model using magnetic resonance spectroscopy and
pubmed: 23345160 doi: 10.1158/0008-5472.CAN-12-2532
Andreou, C., Weissleder, R. & Kircher, M. F. Multiplexed imaging in oncology. Nat. Biomed. Eng. 6, 527–540 (2022).
pubmed: 35624151 doi: 10.1038/s41551-022-00891-5
Disselhorst, J. A. et al. Linking imaging to omics utilizing image-guided tissue extraction. Proc. Natl Acad. Sci. USA 115, E2980–E2987 (2018).
pubmed: 29507209 pmcid: 5879681 doi: 10.1073/pnas.1718304115
Trautwein, C. et al. Tissue metabolites in diffuse glioma and their modulations by IDH1 mutation, histology, and treatment. JCI Insight https://doi.org/10.1172/jci.insight.153526 (2022).
doi: 10.1172/jci.insight.153526 pubmed: 34941573 pmcid: 8855807
Mu, W. et al. Non-invasive decision support for NSCLC treatment using PET/CT radiomics. Nat. Commun. 11, 5228 (2020).
pubmed: 33067442 pmcid: 7567795 doi: 10.1038/s41467-020-19116-x
Stumpo, V. et al. Feasibility of glioblastoma tissue response mapping with physiologic BOLD imaging using precise oxygen and carbon dioxide challenge. MAGMA 35, 29–44 (2022).
pubmed: 34874499 doi: 10.1007/s10334-021-00980-7
Zhang, L. et al. Lanthanide-based T2ex and CEST complexes provide insights into the design of pH sensitive MRI agents. Angew. Chem. Int. Ed. Engl. 56, 16626–16630 (2017).
pubmed: 29024242 pmcid: 5879776 doi: 10.1002/anie.201707959
Giger, M. L. Machine learning in medical imaging. J. Am. Coll. Radiol. 15, 512–520 (2018).
pubmed: 29398494 doi: 10.1016/j.jacr.2017.12.028
Hosny, A., Parmar, C., Quackenbush, J., Schwartz, L. H. & Aerts, H. Artificial intelligence in radiology. Nat. Rev. Cancer 18, 500–510 (2018).
pubmed: 29777175 pmcid: 6268174 doi: 10.1038/s41568-018-0016-5
Gillies, R. J., Kinahan, P. E. & Hricak, H. Radiomics: images are more than pictures, they are data. Radiology 278, 563–577 (2016). This review provides an overview of radiomics — the convergence of imaging and genetic profiling.
pubmed: 26579733 doi: 10.1148/radiol.2015151169
Tomaszewski, M. R. & Gillies, R. J. The biological meaning of radiomic features. Radiology 298, 505–516 (2021).
pubmed: 33399513 doi: 10.1148/radiol.2021202553
Mu, W., Schabath, M. B. & Gillies, R. J. Images are data: challenges and opportunities in the clinical translation of radiomics. Cancer Res. 82, 2066–2068 (2022).
pubmed: 35661199 doi: 10.1158/0008-5472.CAN-22-1183
Sharma, A., Lelic, D., Brock, C., Paine, P. & Aziz, Q. New technologies to investigate the brain–gut axis. World J. Gastroenterol. 15, 182–191 (2009).
pubmed: 19132768 pmcid: 2653301 doi: 10.3748/wjg.15.182
Rosen, S. D. & Camici, P. G. The brain–heart axis in the perception of cardiac pain: the elusive link between ischaemia and pain. Ann. Med. 32, 350–364 (2000).
pubmed: 10949067 doi: 10.3109/07853890008995938
Badawi, R. D. et al. First human imaging studies with the EXPLORER Total-Body PET scanner. J. Nucl. Med. 60, 299–303 (2019). This study is one of the first publications of total-body human PET imaging.
pubmed: 30733314 pmcid: 6424228 doi: 10.2967/jnumed.119.226498
Lammertsma, A. A. Quantification of PET studies. J. Nucl. Cardiol. 26, 2045–2047 (2019).
pubmed: 30644053 doi: 10.1007/s12350-018-01583-x
Cherry, S. R. et al. Total-body imaging: transforming the role of positron emission tomography. Sci. Transl. Med. https://doi.org/10.1126/scitranslmed.aaf6169 (2017). This review describes total-body PET, from initial ideas to applications.
doi: 10.1126/scitranslmed.aaf6169 pubmed: 28298419 pmcid: 5629037
Prenosil, G. A. et al. Performance characteristics of the biograph vision quadra PET/CT system with long axial field of view using the NEMA NU 2-2018 standard. J. Nucl. Med. https://doi.org/10.2967/jnumed.121.261972 (2021).
doi: 10.2967/jnumed.121.261972 pubmed: 34301780
Ibaraki, M. et al. Brain partial volume correction with point spreading function reconstruction in high-resolution digital PET: comparison with an MR-based method in FDG imaging. Ann. Nucl. Med. 36, 717–727 (2022).
pubmed: 35616808 pmcid: 9304042 doi: 10.1007/s12149-022-01753-5
Grimm, J., Kiessling, F. & Pichler, B. J. Quo vadis, molecular imaging? J. Nucl. Med. 61, 1428–1434 (2020). This review describes molecular imaging methods in general and provides an overview of imaging PET tracers, from small molecules to biologicals.
pubmed: 32859706 doi: 10.2967/jnumed.120.241984
Boellaard, R. et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur. J. Nucl. Med. Mol. Imaging 42, 328–354 (2015).
pubmed: 25452219 doi: 10.1007/s00259-014-2961-x
Jadvar, H. Is there use for FDG-PET in prostate cancer? Semin. Nucl. Med. 46, 502–506 (2016).
pubmed: 27825430 pmcid: 5119923 doi: 10.1053/j.semnuclmed.2016.07.004
Sharma, P. et al. Comparison of the prognostic values of
pubmed: 25030618 doi: 10.1007/s00259-014-2850-3
Kayani, I. et al. Functional imaging of neuroendocrine tumors with combined PET/CT using
pubmed: 18383518 doi: 10.1002/cncr.23469
Schuster, D. M., Nanni, C. & Fanti, S. PET tracers beyond FDG in prostate cancer. Semin. Nucl. Med. 46, 507–521 (2016).
pubmed: 27825431 pmcid: 5117950 doi: 10.1053/j.semnuclmed.2016.07.005
Buteau, J. P. et al. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [
pubmed: 36261050 doi: 10.1016/S1470-2045(22)00605-2
Squires, M. H. 3rd et al. Octreoscan versus FDG-PET for neuroendocrine tumor staging: a biological approach. Ann. Surg. Oncol. 22, 2295–2301 (2015).
pubmed: 25786743 doi: 10.1245/s10434-015-4471-x
Alevroudis, E. et al. Clinical utility of
doi: 10.3390/cancers13081813 pubmed: 33920195 pmcid: 8069875
Bhandari, V. et al. Molecular landmarks of tumor hypoxia across cancer types. Nat. Genet. 51, 308–318 (2019).
pubmed: 30643250 doi: 10.1038/s41588-018-0318-2
Liu, T. et al. Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy. J. Hematol. Oncol. 12, 86 (2019).
pubmed: 31462327 pmcid: 6714445 doi: 10.1186/s13045-019-0770-1
Petrova, V., Annicchiarico-Petruzzelli, M., Melino, G. & Amelio, I. The hypoxic tumour microenvironment. Oncogenesis 7, 10 (2018).
pubmed: 29362402 pmcid: 5833859 doi: 10.1038/s41389-017-0011-9
Wilson, W. R. & Hay, M. P. Targeting hypoxia in cancer therapy. Nat. Rev. Cancer 11, 393–410 (2011).
pubmed: 21606941 doi: 10.1038/nrc3064
Masaki, Y. et al. The accumulation mechanism of the hypoxia imaging probe ‘FMISO’ by imaging mass spectrometry: possible involvement of low-molecular metabolites. Sci. Rep. 5, 16802 (2015).
pubmed: 26582591 pmcid: 4652161 doi: 10.1038/srep16802
Reischl, G. et al. Preparation of the hypoxia imaging PET tracer [
pubmed: 15799867 doi: 10.1016/j.apradiso.2004.12.004
Fleming, I. N. et al. Imaging tumour hypoxia with positron emission tomography. Br. J. Cancer 112, 238–250 (2015).
pubmed: 25514380 doi: 10.1038/bjc.2014.610
Busk, M., Overgaard, J. & Horsman, M. R. Imaging of tumor hypoxia for radiotherapy: current status and future directions. Semin. Nucl. Med. 50, 562–583 (2020).
pubmed: 33059825 doi: 10.1053/j.semnuclmed.2020.05.003
Anemone, A., Consolino, L., Arena, F., Capozza, M. & Longo, D. L. Imaging tumor acidosis: a survey of the available techniques for mapping in vivo tumor pH. Cancer Metast. Rev. 38, 25–49 (2019).
doi: 10.1007/s10555-019-09782-9
Noman, M. Z. et al. Hypoxia: a key player in antitumor immune response. A review in the theme: cellular responses to hypoxia. Am. J. Physiol. Cell Physiol. 309, C569–C579 (2015).
pubmed: 26310815 pmcid: 4628936 doi: 10.1152/ajpcell.00207.2015
Lopes, S., Ferreira, S. & Caetano, M. PET/CT in the evaluation of hypoxia for radiotherapy planning in head and neck tumors: systematic literature review. J. Nucl. Med. Technol. 49, 107–113 (2021).
pubmed: 33361182 doi: 10.2967/jnmt.120.249540
Gerard, M. et al. Hypoxia imaging and adaptive radiotherapy: a state-of-the-art approach in the management of glioma. Front. Med. 6, 117 (2019).
doi: 10.3389/fmed.2019.00117
Dirix, P. et al. Dose painting in radiotherapy for head and neck squamous cell carcinoma: value of repeated functional imaging with
pubmed: 19525447 doi: 10.2967/jnumed.109.062638
Melsens, E. et al. Hypoxia imaging with
pubmed: 29514673 pmcid: 5842657 doi: 10.1186/s13014-018-0984-3
Carmona-Bozo, J. C. et al. Hypoxia and perfusion in breast cancer: simultaneous assessment using PET/MR imaging. Eur. Radiol. 31, 333–344 (2021).
pubmed: 32725330 doi: 10.1007/s00330-020-07067-2
Stegmayr, C. et al. Current trends in the use of O-(2-[
pubmed: 32113820 doi: 10.1016/j.nucmedbio.2020.02.006
Stegmayr, C., Willuweit, A., Lohmann, P. & Langen, K. J. O-(2-[
doi: 10.2174/1874471012666190111111046
Zanoni, L. et al. Role of
doi: 10.1007/s00259-019-04323-6
Bashir, A. et al. PET imaging of meningioma with
doi: 10.1093/brain/awaa267
Buck, A. K. et al. Imaging proliferation in lung tumors with PET:
Vesselle, H. et al. In vivo validation of 3′deoxy-3′-[
Shinomiya, A. et al. Evaluation of 3′-deoxy-3′-[
pubmed: 23229746 doi: 10.1007/s00259-012-2275-9
Brockenbrough, J. S. et al. Tumor 3′-deoxy-3′-
pubmed: 21764789 doi: 10.2967/jnumed.111.089482
Schwenck, J. et al. Comparison of
pubmed: 27557844 doi: 10.1007/s00259-016-3490-6
Ambrosini, V., Campana, D., Tomassetti, P. & Fanti, S.
pubmed: 22388622 doi: 10.1007/s00259-011-1989-4
Sartor, O. & de Bono, J. S. Metastatic prostate cancer. N. Engl. J. Med. 378, 1653–1654 (2018).
pubmed: 29694820 doi: 10.1056/NEJMra1701695
Oberg, K., Knigge, U., Kwekkeboom, D., Perren, A. & Group, E. G. W. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 23, vii124–vii130 (2012).
doi: 10.1093/annonc/mds295
Langbein, T., Weber, W. A. & Eiber, M. Future of theranostics: an outlook on precision oncology in nuclear medicine. J. Nucl. Med. 60, 13S–19S (2019). Together with Hermann et al. (2020), this review discusses theranostics in nuclear medicine and precision oncology.
doi: 10.2967/jnumed.118.220566
Hofman, M. S. et al. [
doi: 10.1016/S0140-6736(21)00237-3
Sartor, O. et al. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. N. Engl. J. Med. 385, 1091–1103 (2021).
pmcid: 8446332 doi: 10.1056/NEJMoa2107322
Strosberg, J. et al. Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with
pmcid: 6366953 doi: 10.1200/JCO.2018.78.5865
Hofman, M. S. et al. [
doi: 10.1016/S1470-2045(18)30198-0
Strosberg, J. et al. Phase 3 trial of
pmcid: 5895095 doi: 10.1056/NEJMoa1607427
Backhaus, P. et al. Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives. Eur. J. Nucl. Med. Mol. Imaging 45, 860–877 (2018).
doi: 10.1007/s00259-017-3922-y
Gao, Y. et al. Prostate-specific membrane antigen (PSMA) promotes angiogenesis of glioblastoma through interacting with ITGB4 and regulating NF-κB signaling pathway. Front. Cell Dev. Biol. 9, 598377 (2021).
pmcid: 7969793 doi: 10.3389/fcell.2021.598377
Silver, D. A., Pellicer, I., Fair, W. R., Heston, W. D. & Cordon-Cardo, C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res. 3, 81–85 (1997).
Schwenck, J. et al. In vivo visualization of prostate-specific membrane antigen in glioblastoma. Eur. J. Nucl. Med. Mol. Imaging 42, 170–171 (2015).
pubmed: 25293865 doi: 10.1007/s00259-014-2921-5
Wernicke, A. G. et al. Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiforme. Arch. Pathol. Lab. Med. 135, 1486–1489 (2011).
pubmed: 22032578 doi: 10.5858/arpa.2010-0740-OA
Wernicke, A. G. et al. Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers. APMIS 122, 482–489 (2014).
pubmed: 24304465 doi: 10.1111/apm.12195
Sollini, M. et al. PSMA expression level predicts differentiated thyroid cancer aggressiveness and patient outcome. EJNMMI Res. 9, 93 (2019).
pubmed: 31617002 pmcid: 6794333 doi: 10.1186/s13550-019-0559-9
Schmidt, L. H. et al. Prostate specific membrane antigen (PSMA) expression in non-small cell lung cancer. PLoS ONE 12, e0186280 (2017).
pubmed: 29077706 pmcid: 5659610 doi: 10.1371/journal.pone.0186280
Hirmas, N. et al.
pubmed: 33509970 pmcid: 8882890 doi: 10.2967/jnumed.120.257915
Kesler, M. et al.
pubmed: 30002112 doi: 10.2967/jnumed.118.214833
Jiao, D. et al. Expression of prostate-specific membrane antigen in tumor-associated vasculature predicts poor prognosis in hepatocellular carcinoma. Clin. Transl. Gastroenterol. 10, e00041 (2019).
pubmed: 31116141 pmcid: 6602770 doi: 10.14309/ctg.0000000000000041
Conway, R. E. et al. Prostate specific membrane antigen produces pro-angiogenic laminin peptides downstream of matrix metalloprotease-2. Angiogenesis 16, 847–860 (2013).
pubmed: 23775497 doi: 10.1007/s10456-013-9360-y
Conway, R. E. et al. Prostate-specific membrane antigen (PSMA)-mediated laminin proteolysis generates a pro-angiogenic peptide. Angiogenesis 19, 487–500 (2016).
doi: 10.1007/s10456-016-9521-x
Papetti, M. & Herman, I. M. Mechanisms of normal and tumor-derived angiogenesis. Am. J. Physiol. Cell Physiol. 282, C947–C970 (2002).
pubmed: 11940508 doi: 10.1152/ajpcell.00389.2001
Holzgreve, A. et al. PSMA expression in glioblastoma as a basis for theranostic approaches: a retrospective, correlational panel study including immunohistochemistry, clinical parameters and PET imaging. Front. Oncol. 11, 646387 (2021).
pubmed: 33859946 pmcid: 8042319 doi: 10.3389/fonc.2021.646387
Rizzo, A. et al. Can PSMA-targeting radiopharmaceuticals be useful for detecting hepatocellular carcinoma using positron emission tomography? An updated systematic review and meta-analysis. Pharmaceuticals 15, 1368 (2022).
pubmed: 36355540 pmcid: 9699564 doi: 10.3390/ph15111368
Derlin, T., Kreipe, H. H., Schumacher, U. & Soudah, B. PSMA expression in tumor neovasculature endothelial cells of follicular thyroid adenoma as identified by molecular imaging using 68Ga-PSMA ligand PET/CT. Clin. Nucl. Med. 42, e173–e174 (2017).
pubmed: 27997422 doi: 10.1097/RLU.0000000000001487
Kunikowska, J. et al. Tumor uptake in glioblastoma multiforme after IV injection of [
pubmed: 32040612 pmcid: 7188710 doi: 10.1007/s00259-020-04715-z
Uijen, M. J. M. et al. PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports. Eur. J. Nucl. Med. Mol. Imaging 48, 4350–4368 (2021).
pubmed: 34120192 pmcid: 8566635 doi: 10.1007/s00259-021-05433-w
Schulz, G. et al. Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res. 44, 5914–5920 (1984).
pubmed: 6498849
Schmitt, J. et al. Translational immunoPET imaging using a radiolabeled GD2-specific antibody in neuroblastoma. Theranostics https://doi.org/10.7150/thno.56736 (2022).
doi: 10.7150/thno.56736 pubmed: 35966592 pmcid: 9373823
Butch, E. R. et al. Positron emission tomography detects in vivo expression of disialoganglioside GD2 in mouse models of primary and metastatic osteosarcoma. Cancer Res. 79, 3112–3124 (2019).
pubmed: 31015228 pmcid: 6571039 doi: 10.1158/0008-5472.CAN-18-3340
Trautwein, N. F. et al. First in human PET/MRI imaging of in vivo GD2 expression in osteosarcoma. J. Nucl. Med. https://doi.org/10.2967/jnumed.122.264626 (2022).
doi: 10.2967/jnumed.122.264626 pubmed: 36109181
Navid, F., Santana, V. M. & Barfield, R. C. Anti-GD2 antibody therapy for GD2-expressing tumors. Curr. Cancer Drug Targets 10, 200–209 (2010).
pubmed: 20201786 pmcid: 2888262 doi: 10.2174/156800910791054167
Ploessl, C., Pan, A., Maples, K. T. & Lowe, D. K. Dinutuximab: an anti-GD2 monoclonal antibody for high-risk neuroblastoma. Ann. Pharmacother. 50, 416–422 (2016).
pubmed: 26917818 doi: 10.1177/1060028016632013
Schumacher-Kuckelkorn, R. et al. Lack of immunocytological GD2 expression on neuroblastoma cells in bone marrow at diagnosis, during treatment, and at recurrence. Pediatr. Blood Cancer 64, 46–56 (2017).
pubmed: 27654028 doi: 10.1002/pbc.26184
Anderson, N. M. & Simon, M. C. The tumor microenvironment. Curr. Biol. 30, R921–R925 (2020).
pubmed: 32810447 pmcid: 8194051 doi: 10.1016/j.cub.2020.06.081
Kalluri, R. The biology and function of fibroblasts in cancer. Nat. Rev. Cancer 16, 582–598 (2016).
pubmed: 27550820 doi: 10.1038/nrc.2016.73
Kim, I., Choi, S., Yoo, S., Lee, M. & Kim, I. S. Cancer-associated fibroblasts in the hypoxic tumor microenvironment. Cancers https://doi.org/10.3390/cancers14143321 (2022).
doi: 10.3390/cancers14143321 pubmed: 36612289 pmcid: 9818958
Madsen, C. D. et al. Hypoxia and loss of PHD2 inactivate stromal fibroblasts to decrease tumour stiffness and metastasis. EMBO Rep. 16, 1394–1408 (2015).
pubmed: 26323721 pmcid: 4662858 doi: 10.15252/embr.201540107
Pure, E. & Blomberg, R. Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics. Oncogene 37, 4343–4357 (2018).
pubmed: 29720723 pmcid: 6092565 doi: 10.1038/s41388-018-0275-3
Loktev, A. et al. A tumor-imaging method targeting cancer-associated fibroblasts. J. Nucl. Med. 59, 1423–1429 (2018).
pubmed: 29626120 pmcid: 6126438 doi: 10.2967/jnumed.118.210435
Lindner, T. et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J. Nucl. Med. 59, 1415–1422 (2018).
pubmed: 29626119 doi: 10.2967/jnumed.118.210443
Kratochwil, C. et al.
pubmed: 30954939 pmcid: 6581228 doi: 10.2967/jnumed.119.227967
Koerber, S. A. et al. The role of
pubmed: 32060216 pmcid: 9374030 doi: 10.2967/jnumed.119.237016
Komek, H. et al. Comparison of [
pubmed: 35578038 doi: 10.1007/s00259-022-05839-0
Gu, B. et al. Head-to-head evaluation of [
pubmed: 35113192 pmcid: 9206606 doi: 10.1007/s00259-022-05700-4
Lindner, T. et al. Design and development of
pubmed: 32169911 pmcid: 7539653 doi: 10.2967/jnumed.119.239731
Ballal, S. et al. A theranostic approach of [
doi: 10.1007/s00259-020-04990-w pubmed: 33244617
Vasan, N., Baselga, J. & Hyman, D. M. A view on drug resistance in cancer. Nature 575, 299–309 (2019).
pubmed: 31723286 pmcid: 8008476 doi: 10.1038/s41586-019-1730-1
Wang, L., Lankhorst, L. & Bernards, R. Exploiting senescence for the treatment of cancer. Nat. Rev. Cancer 22, 340–355 (2022). This review discusses tumour senescence and novel treatment options based on this phenomenon.
pubmed: 35241831 doi: 10.1038/s41568-022-00450-9
Bodnar, A. G. et al. Extension of life-span by introduction of telomerase into normal human cells. Science 279, 349–352 (1998).
pubmed: 9454332 doi: 10.1126/science.279.5349.349
Hayflick, L. & Moorhead, P. S. The serial cultivation of human diploid cell strains. Exp. Cell Res. 25, 585–621 (1961).
pubmed: 13905658 doi: 10.1016/0014-4827(61)90192-6
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D. & Lowe, S. W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16
pubmed: 9054499 doi: 10.1016/S0092-8674(00)81902-9
Demaria, M. et al. An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA. Dev. Cell 31, 722–733 (2014).
pubmed: 25499914 pmcid: 4349629 doi: 10.1016/j.devcel.2014.11.012
Liao, E. C. et al. Radiation induces senescence and a bystander effect through metabolic alterations. Cell Death Dis. 5, e1255 (2014).
pubmed: 24853433 pmcid: 4047910 doi: 10.1038/cddis.2014.220
Chang, B. D. et al. Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene 18, 4808–4818 (1999).
pubmed: 10490814 doi: 10.1038/sj.onc.1203078
Munoz-Espin, D. & Serrano, M. Cellular senescence: from physiology to pathology. Nat. Rev. Mol. Cell Biol. 15, 482–496 (2014).
pubmed: 24954210 doi: 10.1038/nrm3823
Birch, J. & Gil, J. Senescence and the SASP: many therapeutic avenues. Genes Dev. 34, 1565–1576 (2020).
pubmed: 33262144 pmcid: 7706700 doi: 10.1101/gad.343129.120
Coppe, J. P. et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 6, 2853–2868 (2008).
pubmed: 19053174 doi: 10.1371/journal.pbio.0060301
Schmitt, C. A., Wang, B. & Demaria, M. Senescence and cancer — role and therapeutic opportunities. Nat. Rev. Clin. Oncol. 19, 619–636 (2022).
pubmed: 36045302 pmcid: 9428886 doi: 10.1038/s41571-022-00668-4
Demaria, M. et al. Cellular senescence promotes adverse effects of chemotherapy and cancer relapse. Cancer Discov. 7, 165–176 (2017).
pubmed: 27979832 doi: 10.1158/2159-8290.CD-16-0241
Faheem, M. M. et al. Convergence of therapy-induced senescence (TIS) and EMT in multistep carcinogenesis: current opinions and emerging perspectives. Cell Death Discov. 6, 51 (2020).
pubmed: 32566256 pmcid: 7295779 doi: 10.1038/s41420-020-0286-z
Faget, D. V., Ren, Q. & Stewart, S. A. Unmasking senescence: context-dependent effects of SASP in cancer. Nat. Rev. Cancer 19, 439–453 (2019).
pubmed: 31235879 doi: 10.1038/s41568-019-0156-2
Zhao, B. et al. Topoisomerase 1 cleavage complex enables pattern recognition and inflammation during senescence. Nat. Commun. 11, 908 (2020).
pubmed: 32075966 pmcid: 7031389 doi: 10.1038/s41467-020-14652-y
Wang, C. et al. Inducing and exploiting vulnerabilities for the treatment of liver cancer. Nature 574, 268–272 (2019).
pubmed: 31578521 pmcid: 6858884 doi: 10.1038/s41586-019-1607-3
Coppe, J. P., Desprez, P. Y., Krtolica, A. & Campisi, J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu. Rev. Pathol. 5, 99–118 (2010).
pubmed: 20078217 pmcid: 4166495 doi: 10.1146/annurev-pathol-121808-102144
Tchkonia, T., Zhu, Y., van Deursen, J., Campisi, J. & Kirkland, J. L. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J. Clin. Invest. 123, 966–972 (2013).
pubmed: 23454759 pmcid: 3582125 doi: 10.1172/JCI64098
Zhang, L., Pitcher, L. E., Prahalad, V., Niedernhofer, L. J. & Robbins, P. D. Targeting cellular senescence with senotherapeutics: senolytics and senomorphics. FEBS J. https://doi.org/10.1111/febs.16350 (2022).
doi: 10.1111/febs.16350 pubmed: 36536996 pmcid: 10087799
Laberge, R. M. et al. MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation. Nat. Cell Biol. 17, 1049–1061 (2015).
pubmed: 26147250 pmcid: 4691706 doi: 10.1038/ncb3195
Wolter, K. & Zender, L. Therapy-induced senescence — an induced synthetic lethality in liver cancer? Nat. Rev. Gastroenterol. Hepatol. 17, 135–136 (2020).
pubmed: 31965074 doi: 10.1038/s41575-020-0262-3
Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883–892 (2012).
pubmed: 22397650 pmcid: 4878653 doi: 10.1056/NEJMoa1113205
Yachida, S. et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467, 1114–1117 (2010).
pubmed: 20981102 pmcid: 3148940 doi: 10.1038/nature09515
Lawson, D. A., Kessenbrock, K., Davis, R. T., Pervolarakis, N. & Werb, Z. Tumour heterogeneity and metastasis at single-cell resolution. Nat. Cell Biol. 20, 1349–1360 (2018).
pubmed: 30482943 pmcid: 6477686 doi: 10.1038/s41556-018-0236-7
Ding, L. et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464, 999–1005 (2010).
pubmed: 20393555 pmcid: 2872544 doi: 10.1038/nature08989
Krueger, M. A. et al. Abstract 1146: [
doi: 10.1158/1538-7445.AM2019-1146
Lee, B. Y. et al. Senescence-associated beta-galactosidase is lysosomal beta-galactosidase. Aging Cell 5, 187–195 (2006).
pubmed: 16626397 doi: 10.1111/j.1474-9726.2006.00199.x
Short, S., Fielder, E., Miwa, S. & von Zglinicki, T. Senolytics and senostatics as adjuvant tumour therapy. eBioMedicine 41, 683–692 (2019).
pubmed: 30737084 pmcid: 6441870 doi: 10.1016/j.ebiom.2019.01.056
Lord, C. J. & Ashworth, A. PARP inhibitors: synthetic lethality in the clinic. Science 355, 1152–1158 (2017).
pubmed: 28302823 pmcid: 6175050 doi: 10.1126/science.aam7344
Pommier, Y., O’Connor, M. J. & de Bono, J. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action. Sci. Transl. Med. 8, 362ps317 (2016).
doi: 10.1126/scitranslmed.aaf9246
Audeh, M. W. et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376, 245–251 (2010).
pubmed: 20609468 doi: 10.1016/S0140-6736(10)60893-8
Fong, P. C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123–134 (2009).
pubmed: 19553641 doi: 10.1056/NEJMoa0900212
Maughan, B. L. & Antonarakis, E. S. Olaparib and rucaparib for the treatment of DNA repair-deficient metastatic castration-resistant prostate cancer. Exp. Opin. Pharmacother. 22, 1625–1632 (2021).
doi: 10.1080/14656566.2021.1912015
Rose, M., Burgess, J. T., O’Byrne, K., Richard, D. J. & Bolderson, E. PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance. Front. Cell Dev. Biol. 8, 564601 (2020).
pubmed: 33015058 pmcid: 7509090 doi: 10.3389/fcell.2020.564601
Ashworth, A. & Lord, C. J. Synthetic lethal therapies for cancer: what’s next after PARP inhibitors? Nat. Rev. Clin. Oncol. 15, 564–576 (2018).
pubmed: 29955114 doi: 10.1038/s41571-018-0055-6
Michels, J. et al. Cisplatin resistance associated with PARP hyperactivation. Cancer Res. 73, 2271–2280 (2013).
pubmed: 23554447 doi: 10.1158/0008-5472.CAN-12-3000
Lord, C. J., Tutt, A. N. & Ashworth, A. Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. Annu. Rev. Med. 66, 455–470 (2015).
pubmed: 25341009 doi: 10.1146/annurev-med-050913-022545
Yi, M. et al. Advances and perspectives of PARP inhibitors. Exp. Hematol. Oncol. 8, 29 (2019).
pubmed: 31737426 pmcid: 6849303 doi: 10.1186/s40164-019-0154-9
Banerjee, S. et al. First-line PARP inhibitors in ovarian cancer: summary of an ESMO open — cancer horizons round-table discussion. ESMO Open 5, e001110 (2020).
pubmed: 33310779 pmcid: 7783599 doi: 10.1136/esmoopen-2020-001110
Tu, Z. et al. Synthesis and in vivo evaluation of [
pubmed: 15982573 doi: 10.1016/j.nucmedbio.2005.03.001
Makvandi, M. et al. A PET imaging agent for evaluating PARP-1 expression in ovarian cancer. J. Clin. Invest. 128, 2116–2126 (2018).
pubmed: 29509546 pmcid: 5919879 doi: 10.1172/JCI97992
Carney, B., Kossatz, S. & Reiner, T. Molecular imaging of PARP. J. Nucl. Med. 58, 1025–1030 (2017).
pubmed: 28473593 pmcid: 5493005 doi: 10.2967/jnumed.117.189936
Carney, B. et al. Target engagement imaging of PARP inhibitors in small-cell lung cancer. Nat. Commun. 9, 176 (2018).
pubmed: 29330466 pmcid: 5766608 doi: 10.1038/s41467-017-02096-w
McDonald, E. S. et al. Positron emission tomography imaging of poly-(adenosine diphosphate-ribose) polymerase 1 expression in breast cancer: a nonrandomized clinical trial. JAMA Oncol. 6, 921–923 (2020).
pubmed: 32297911 pmcid: 7163777 doi: 10.1001/jamaoncol.2020.0334
Schoder, H. et al. Safety and feasibility of PARP1/2 imaging with
pubmed: 32245901 pmcid: 7421489 doi: 10.1158/1078-0432.CCR-19-3484
Michel, L. S. et al. PET of poly (ADP-ribose) polymerase activity in cancer: preclinical assessment and first in-human studies. Radiology 282, 453–463 (2017).
pubmed: 27841728 doi: 10.1148/radiol.2016161929
Fan, Y. et al. Progress of immune checkpoint therapy in the clinic (Review). Oncol. Rep. 41, 3–14 (2019).
pubmed: 30365127
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S. & Milone, M. C. CAR T cell immunotherapy for human cancer. Science 359, 1361–1365 (2018).
pubmed: 29567707 doi: 10.1126/science.aar6711
Freise, A. C. & Wu, A. M. In vivo imaging with antibodies and engineered fragments. Mol. Immunol. 67, 142–152 (2015). This review discusses PET imaging of the immune system with biologicals.
pubmed: 25934435 pmcid: 4529772 doi: 10.1016/j.molimm.2015.04.001
Bensch, F. et al. (89)Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nat. Med. 24, 1852–1858 (2018). This study presents PET immune imaging of PDL1.
pubmed: 30478423 doi: 10.1038/s41591-018-0255-8
Kristensen, L. K. et al. CD4
pubmed: 31754392 pmcid: 6857046 doi: 10.7150/thno.37513
Tavaré, R. et al. Engineered antibody fragments for immuno-PET imaging of endogenous CD8+ T cells in vivo. Proc. Natl Acad. Sci. USA 111, 1108–1113 (2014).
pubmed: 24390540 pmcid: 3903195 doi: 10.1073/pnas.1316922111
Tavaré, R. et al. Immuno-PET of murine T cell reconstitution postadoptive stem cell transplantation using anti-CD4 and anti-CD8 Cys-diabodies. J. Nucl. Med. 56, 1258–1264 (2015).
pubmed: 25952734 doi: 10.2967/jnumed.114.153338
Lecocq, Q. et al. Theranostics in immuno-oncology using nanobody derivatives. Theranostics 9, 7772–7791 (2019).
pmcid: 6831473 doi: 10.7150/thno.34941
van der Linden, R. H. et al. Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies. Biochim. Biophys. Acta 1431, 37–46 (1999).
doi: 10.1016/S0167-4838(99)00030-8
Rashidian, M. & Ploegh, H. Nanobodies as non-invasive imaging tools. Immuno-Oncol. Technol. 7, 2–14 (2020).
doi: 10.1016/j.iotech.2020.07.001
Gide, T. N. et al. Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1/anti-CTLA-4 combined therapy. Cancer Cell 35, 238–255.e6 (2019).
doi: 10.1016/j.ccell.2019.01.003
Thorsson, V. et al. The immune landscape of cancer. Immunity 48, 812–830.e4 (2018).
pubmed: 29628290 pmcid: 5982584 doi: 10.1016/j.immuni.2018.03.023
Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960–1964 (2006).
pubmed: 17008531 doi: 10.1126/science.1129139
Klein, O. et al. Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. Clin. Cancer Res. 15, 2507–2513 (2009).
pubmed: 19318477 doi: 10.1158/1078-0432.CCR-08-2424
Tavare, R. et al. An effective immuno-PET imaging method to monitor CD8-dependent responses to immunotherapy. Cancer Res. 76, 73–82 (2016).
pubmed: 26573799 doi: 10.1158/0008-5472.CAN-15-1707
Rashidian, M. et al. Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells. J. Exp. Med. 214, 2243–2255 (2017).
pubmed: 28666979 pmcid: 5551571 doi: 10.1084/jem.20161950
Freise, A. C. et al. ImmunoPET imaging of murine CD4
pubmed: 27966069 pmcid: 5524218 doi: 10.1007/s11307-016-1032-z
Griessinger, C. M. et al. The PET-tracer 89Zr-Df-IAB22M2C enables monitoring of intratumoral CD8 T-cell infiltrates in tumor-bearing humanized mice after T-cell bispecific antibody treatment. Cancer Res. 80, 2903 (2020).
pubmed: 32409308 doi: 10.1158/0008-5472.CAN-19-3269
Pandit-Taskar, N. et al. First in human phase I imaging study with 89Zr-IAB22M2C anti-CD8 minibody in patients with solid tumors. J. Nucl. Med. 59, 596 (2018).
US National Library of Medicine. ClinicalTrials.gov, http://www.clinicaltrials.gov/ct2/show/NCT03802123 (2019).
US National Library of Medicine. ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT05397171 (2022).
US National Library of Medicine. ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT05744128 (2023).
EU Clinical Trials Register. https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-004328-004313/DE (2022).
Kist de Ruijter, L. et al. Whole-body CD8
pubmed: 36471036 pmcid: 9800278 doi: 10.1038/s41591-022-02084-8
Ahrends, T. & Borst, J. The opposing roles of CD4
pmcid: 6050207 doi: 10.1111/imm.12941
Di Mascio, M. et al. Noninvasive in vivo imaging of CD4 cells in simian-human immunodeficiency virus (SHIV)-infected nonhuman primates. Blood 114, 328–337 (2009).
pmcid: 2714208 doi: 10.1182/blood-2008-12-192203
Kanwar, B. et al. In vivo imaging of mucosal CD4
doi: 10.1016/j.jim.2007.09.008
Rubin, R. H., Baltimore, D., Chen, B. K., Wilkinson, R. A. & Fischman, A. J. In vivo tissue distribution of CD4 lymphocytes in mice determined by radioimmunoscintigraphy with an 111In-labeled anti-CD4 monoclonal antibody. Proc. Natl Acad. Sci. USA 93, 7460–7463 (1996).
pubmed: 8755495 pmcid: 38766 doi: 10.1073/pnas.93.15.7460
Choy, E. H. et al. Repeat-cycle study of high-dose intravenous 4162W94 anti-CD4 humanized monoclonal antibody in rheumatoid arthritis. A randomized placebo-controlled trial. Rheumatology 41, 1142–1148 (2002).
pubmed: 12364634 doi: 10.1093/rheumatology/41.10.1142
Harmand, T. J., Islam, A., Pishesha, N. & Ploegh, H. L. Nanobodies as in vivo, non-invasive, imaging agents. RSC Chem. Biol. 2, 685–701 (2021).
pubmed: 34212147 pmcid: 8190910 doi: 10.1039/D1CB00023C
Moreland, L. W. et al. Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate. Arthritis Rheum. 38, 1581–1588 (1995).
pubmed: 7488278 doi: 10.1002/art.1780381109
Traenkle, B. et al. Single-domain antibodies for targeting, detection, and in vivo imaging of human CD4
pubmed: 34956237 pmcid: 8696186 doi: 10.3389/fimmu.2021.799910
Wilde, D. B., Marrack, P., Kappler, J., Dialynas, D. P. & Fitch, F. W. Evidence implicating L3T4 in class II MHC antigen reactivity; monoclonal antibody GK1.5 (anti-L3T4a) blocks class II MHC antigen-specific proliferation, release of lymphokines, and binding by cloned murine helper T lymphocyte lines. J. Immunol. 131, 2178–2183 (1983).
pubmed: 6195255 doi: 10.4049/jimmunol.131.5.2178
Kochenderfer, J. N. et al. Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy. Mol. Ther. 25, 2245–2253 (2017).
pubmed: 28803861 pmcid: 5628864 doi: 10.1016/j.ymthe.2017.07.004
Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439–448 (2018).
pubmed: 29385370 pmcid: 5996391 doi: 10.1056/NEJMoa1709866
Simonetta, F. et al. Molecular imaging of chimeric antigen receptor T cells by ICOS-ImmunoPET. Clin. Cancer Res. 27, 1058 (2021).
pubmed: 33087332 doi: 10.1158/1078-0432.CCR-20-2770
Weist, M. R. et al. PET of adoptively transferred chimeric antigen receptor T cells with
pubmed: 29728514 pmcid: 6167529 doi: 10.2967/jnumed.117.206714
Minn, I. et al. Imaging CAR T cell therapy with PSMA-targeted positron emission tomography. Sci. Adv. 5, eaaw5096 (2019).
pubmed: 31281894 pmcid: 6609218 doi: 10.1126/sciadv.aaw5096
Sellmyer, M. A. et al. Imaging CAR T cell trafficking with eDHFR as a PET reporter gene. Mol. Ther. 28, 42–51 (2020).
pubmed: 31668558 doi: 10.1016/j.ymthe.2019.10.007
Volpe, A. et al. Spatiotemporal PET imaging reveals differences in CAR-T tumor retention in triple-negative breast cancer models. Mol. Ther. 28, 2271–2285 (2020).
pubmed: 32645298 pmcid: 7544977 doi: 10.1016/j.ymthe.2020.06.028
Keu, K. V. et al. Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma. Sci. Transl. Med. 9, eaag2196 (2017).
pubmed: 28100832 pmcid: 5260938 doi: 10.1126/scitranslmed.aag2196
Di Gialleonardo, V., Signore, A., Glaudemans, A. W., Dierckx, R. A. & De Vries, E. F. N-(4-
pubmed: 22499614 doi: 10.2967/jnumed.111.091306
Larimer, B. M. et al. Granzyme B PET imaging as a predictive biomarker of immunotherapy response. Cancer Res. 77, 2318–2327 (2017).
pubmed: 28461564 pmcid: 5474226 doi: 10.1158/0008-5472.CAN-16-3346
Gibson, H. M. et al. IFNgamma PET imaging as a predictive tool for monitoring response to tumor immunotherapy. Cancer Res. 78, 5706–5717 (2018).
pubmed: 30115693 pmcid: 6443251 doi: 10.1158/0008-5472.CAN-18-0253
Radu, C. G. et al. Molecular imaging of lymphoid organs and immune activation by positron emission tomography with a new [
pubmed: 18542051 pmcid: 2720060 doi: 10.1038/nm1724
Salas, J. R. et al.
doi: 10.2967/jnumed.118.210328 pubmed: 29700125 pmcid: 6167535
Alam, I. S. et al. Imaging activated T cells predicts response to cancer vaccines. J. Clin. Invest. 128, 2569–2580 (2018).
pubmed: 29596062 pmcid: 5983309 doi: 10.1172/JCI98509
Pan, Y., Yu, Y., Wang, X. & Zhang, T. Tumor-associated macrophages in tumor immunity. Front. Immunol. 11, 583084 (2020).
pubmed: 33365025 pmcid: 7751482 doi: 10.3389/fimmu.2020.583084
Xiang, X., Wang, J., Lu, D. & Xu, X. Targeting tumor-associated macrophages to synergize tumor immunotherapy. Signal. Transduct. Target. Ther. 6, 75 (2021).
pubmed: 33619259 pmcid: 7900181 doi: 10.1038/s41392-021-00484-9
Mukherjee, S., Sonanini, D., Maurer, A. & Daldrup-Link, H. E. The yin and yang of imaging tumor associated macrophages with PET and MRI. Theranostics 9, 7730–7748 (2019).
pubmed: 31695797 pmcid: 6831464 doi: 10.7150/thno.37306
Blykers, A. et al. PET imaging of macrophage mannose receptor–expressing macrophages in tumor stroma using
pubmed: 26069306 doi: 10.2967/jnumed.115.156828
Movahedi, K. et al. Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages. Cancer Res. 72, 4165 (2012).
pubmed: 22719068 doi: 10.1158/0008-5472.CAN-11-2994
Galli, F. et al. In vivo imaging of natural killer cell trafficking in tumors. J. Nucl. Med. 56, 1575–1580 (2015).
pubmed: 26272812 doi: 10.2967/jnumed.114.152918
Griss, J. et al. B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. Nat. Commun. 10, 4186 (2019).
pubmed: 31519915 pmcid: 6744450 doi: 10.1038/s41467-019-12160-2
Krasniqi, A. et al. Theranostic radiolabeled anti-CD20 sdAb for targeted radionuclide therapy of non-Hodgkin’s lymphoma. Mol. Cancer Ther. 16, 2828 (2017).
pubmed: 29054987 doi: 10.1158/1535-7163.MCT-17-0554
Perez, C. R. & De Palma, M. Engineering dendritic cell vaccines to improve cancer immunotherapy. Nat. Commun. 10, 5408 (2019).
pubmed: 31776331 pmcid: 6881351 doi: 10.1038/s41467-019-13368-y
Ambrosini, V. et al. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. Eur. J. Cancer 146, 56–73 (2021).
pubmed: 33588146 pmcid: 8903070 doi: 10.1016/j.ejca.2021.01.008
Maffey-Steffan, J. et al. The
pubmed: 31776632 doi: 10.1007/s00259-019-04583-2
Agdeppa, E. D. & Spilker, M. E. A review of imaging agent development. AAPS J. 11, 286–299 (2009).
pubmed: 19415506 pmcid: 2691464 doi: 10.1208/s12248-009-9104-5
Farsad, M. FDG PET/CT in the staging of lung cancer. Curr. Radiopharm. 13, 195–203 (2020).
pubmed: 31868151 pmcid: 8206197 doi: 10.2174/1874471013666191223153755
Gandy, N., Arshad, M. A., Park, W. E., Rockall, A. G. & Barwick, T. D. FDG-PET imaging in cervical cancer. Semin. Nucl. Med. 49, 461–470 (2019).
pubmed: 31630730 doi: 10.1053/j.semnuclmed.2019.06.007
Groheux, D. et al.
pubmed: 26834096 doi: 10.2967/jnumed.115.157859
Weber, W. A. Use of PET for monitoring cancer therapy and for predicting outcome. J. Nucl. Med. 46, 983–995 (2005). This review discusses PET imaging in oncology.
pubmed: 15937310
Reinfeld, B. I. et al. Cell-programmed nutrient partitioning in the tumour microenvironment. Nature 593, 282–288 (2021).
pubmed: 33828302 pmcid: 8122068 doi: 10.1038/s41586-021-03442-1
Schwenck, J. et al. Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive in vivo
pubmed: 31903160 pmcid: 6929998 doi: 10.7150/thno.35989
Lee, S. & Schmitt, C. A. The dynamic nature of senescence in cancer. Nat. Cell Biol. 21, 94–101 (2019).
pubmed: 30602768 doi: 10.1038/s41556-018-0249-2
Schmitz, J. et al. Decoding intratumoral heterogeneity of breast cancer by multiparametric in vivo imaging: a translational study. Cancer Res. 76, 5512–5522 (2016).
pubmed: 27466286 pmcid: 5414858 doi: 10.1158/0008-5472.CAN-15-0642
Hallqvist, A. et al. Positron emission tomography and computed tomographic imaging (PET/CT) for dose planning purposes of thoracic radiation with curative intent in lung cancer patients: a systematic review and meta-analysis. Radiother. Oncol. 123, 71–77 (2017).
pubmed: 28284494 doi: 10.1016/j.radonc.2017.02.011
Gehler, B. et al. [
pubmed: 19922642 pmcid: 2785827 doi: 10.1186/1748-717X-4-56
Rogowski, P. et al. Radiotherapy of oligometastatic prostate cancer: a systematic review. Radiat. Oncol. 16, 50 (2021).
pubmed: 33750437 pmcid: 7941976 doi: 10.1186/s13014-021-01776-8
Bashir, A. et al. Recurrent glioblastoma versus late posttreatment changes: diagnostic accuracy of O-(2-[
pubmed: 31618420 pmcid: 6917428 doi: 10.1093/neuonc/noz166
Langen, K. J., Galldiks, N., Hattingen, E. & Shah, N. J. Advances in neuro-oncology imaging. Nat. Rev. Neurol. 13, 279–289 (2017).
pubmed: 28387340 doi: 10.1038/nrneurol.2017.44
Pyka, T. et al. Diagnosis of glioma recurrence using multiparametric dynamic
pubmed: 29803382 doi: 10.1016/j.ejrad.2018.04.003
Waaijer, S. J. H. et al. Molecular imaging in cancer drug development. J. Nucl. Med. 59, 726–732 (2018).
pubmed: 29371402 doi: 10.2967/jnumed.116.188045
Matthews, P. M., Rabiner, E. A., Passchier, J. & Gunn, R. N. Positron emission tomography molecular imaging for drug development. Br. J. Clin. Pharmacol. 73, 175–186 (2012).
pubmed: 21838787 pmcid: 3269576 doi: 10.1111/j.1365-2125.2011.04085.x
Bahce, I. et al. Effects of erlotinib therapy on [
pubmed: 26857779 pmcid: 4746207 doi: 10.1186/s13550-016-0169-8
Oosting, S. F. et al.
pubmed: 25476536 doi: 10.2967/jnumed.114.144840
Contractor, K. B. & Aboagye, E. O. Monitoring predominantly cytostatic treatment response with
pubmed: 19403880 doi: 10.2967/jnumed.108.057273
Pandit-Taskar, N. et al. First-in-humans imaging with
pubmed: 31586002 pmcid: 7198374 doi: 10.2967/jnumed.119.229781
Goggi, J. L. et al. Granzyme B PET imaging of combined chemotherapy and immune checkpoint inhibitor therapy in colon cancer. Mol. Imaging Biol. 23, 714–723 (2021).
pubmed: 33713000 pmcid: 8410722 doi: 10.1007/s11307-021-01596-y

Auteurs

Johannes Schwenck (J)

Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University of Tübingen, Tübingen, Germany.
Nuclear Medicine and Clinical Molecular Imaging, Department of Radiology, Eberhard Karls University of Tübingen, Tübingen, Germany.
Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumour Therapies', Eberhard Karls University, Tübingen, Germany.

Dominik Sonanini (D)

Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University of Tübingen, Tübingen, Germany.
Medical Oncology and Pulmonology, Department of Internal Medicine, Eberhard Karls University of Tübingen, Tübingen, Germany.

Jonathan M Cotton (JM)

Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University of Tübingen, Tübingen, Germany.
Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumour Therapies', Eberhard Karls University, Tübingen, Germany.
ORCID: 0000-0002-2727-7945

Hans-Georg Rammensee (HG)

Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumour Therapies', Eberhard Karls University, Tübingen, Germany.
Department of Immunology, IFIZ Institute for Cell Biology, Eberhard Karls University of Tübingen, Tübingen, Germany.
German Cancer Research Center, German Cancer Consortium DKTK, Partner Site Tübingen, Tübingen, Germany.

Christian la Fougère (C)

Nuclear Medicine and Clinical Molecular Imaging, Department of Radiology, Eberhard Karls University of Tübingen, Tübingen, Germany.
Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumour Therapies', Eberhard Karls University, Tübingen, Germany.
German Cancer Research Center, German Cancer Consortium DKTK, Partner Site Tübingen, Tübingen, Germany.

Lars Zender (L)

Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumour Therapies', Eberhard Karls University, Tübingen, Germany.
Medical Oncology and Pulmonology, Department of Internal Medicine, Eberhard Karls University of Tübingen, Tübingen, Germany.
German Cancer Research Center, German Cancer Consortium DKTK, Partner Site Tübingen, Tübingen, Germany.

Bernd J Pichler (BJ)

Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University of Tübingen, Tübingen, Germany. bernd.pichler@med.uni-tuebingen.de.
Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumour Therapies', Eberhard Karls University, Tübingen, Germany. bernd.pichler@med.uni-tuebingen.de.
German Cancer Research Center, German Cancer Consortium DKTK, Partner Site Tübingen, Tübingen, Germany. bernd.pichler@med.uni-tuebingen.de.
ORCID: 0000-0001-6784-5524

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Advances in PET imaging of cancer.
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Techniques de diagnostic radioisotopique › Scintigraphie › Tomoscintigraphie › Tomographie par émission de positons › Tomographie par émission de positons couplée à la tomodensitométrie › Advances in PET imaging of cancer.
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Techniques de diagnostic radioisotopique › Scintigraphie › Tomoscintigraphie › Tomographie par émission de positons › Advances in PET imaging of cancer.
questionsmedicales.fr › Tumeurs › Advances in PET imaging of cancer.
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Imagerie diagnostique › Tomographie › Imagerie par résonance magnétique › Advances in PET imaging of cancer.
questionsmedicales.fr › Sciences de l'information › Méthodologies informatiques › Algorithmes › Intelligence artificielle › Apprentissage machine › Advances in PET imaging of cancer.